(Q34245983)

31 July 2017

title

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

31 July 2017

main subject

0 references

author name string

Fabien B Vincent

series ordinal

1

1 reference

31 July 2017

Eric F Morand

series ordinal

2

1 reference

31 July 2017

Fabienne Mackay

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Immunology & Cell Biology

31 July 2017

published in

1 reference

31 July 2017

volume

90

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

293-303

1 reference

https://scigraph.springernature.com/pub.10.1038/icb.2011.111

31 July 2017

exact match

0 references

cites work

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Follicular B helper T cells in antibody responses and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF and MyD88 signals promote a lupuslike disease independent of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Raised serum APRIL levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Dysfunctional B cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Systemic lupus erythematosus in the far north of Queensland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Ethnicity and lupus nephritis: an Australian single centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF mediates survival of peripheral immature B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

21 January 2018

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

An APRIL to remember: novel TNF ligands as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF augments certain Th1-associated inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

The innate immune system in SLE: type I interferons and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Distinct profiles of human B cell effector cytokines: a role in immune regulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Adaptation of humoral memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Pharmacological intervention in antibody mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

T cells in the pathogenesis of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Regulation of the T-independent humoral response by TACI

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Synthesis and release of B-lymphocyte stimulator from myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Depletion of B cells in murine lupus: efficacy and resistance

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.111

7 January 2021

Identifiers

DOI

10.1038/ICB.2011.111

1 reference

Dimensions Publication ID

31 July 2017

1038156569

0 references

1 reference